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With Type 2 Diabetes Mellitus Decreases Myocardial
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Objectives This study sought to assess the effects of prolonged caloric restriction in obese patients with type 2 diabetes
mellitus (T2DM) on myocardial triglyceride (TG) content and myocardial function.
Background Myocardial TG content is increased in patients with T2DM and may reflect altered myocardial function. It is un-
known whether myocardial TG content is influenced during a therapeutic intervention.
Methods Myocardial TG content (magnetic resonance [MR] spectroscopy), myocardial function (MR imaging), plasma he-
moglobin A1c, and body mass index (BMI) were measured in 12 obese, insulin-treated T2DM patients before
and after a 16-week very-low-calorie diet (VLCD) (450 kcal/day) to achieve substantial weight loss. Insulin was
stopped during the VLCD.
Results The BMI decreased from 35.6  1.2 kg/m2 (baseline, mean  SEM) to 27.5  1.3 kg/m2 (after the VLCD, p 
0.001) and was associated with an improvement in hemoglobin A1c from 7.9  0.4% (baseline) to 6.3  0.3%
(after the VLCD, p  0.006). Myocardial TG content decreased from 0.88  0.12% to 0.64  0.14%, respec-
tively (p  0.019), and was associated with improved diastolic function (reflected by the ratio between the early
and atrial filling phase) from 1.02  0.08 to 1.18  0.06, respectively (p  0.019).
Conclusions Prolonged caloric restriction in obese T2DM patients decreases BMI and improves glucoregulation associated
with decreased myocardial TG content and improved diastolic heart function. Therefore, myocardial TG stores in
obese patients with T2DM are flexible and amendable to therapeutic intervention by caloric restriction. (J Am
Coll Cardiol 2008;52:1006–12) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.068i
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cbesity and type 2 diabetes mellitus (T2DM) are associated
ith increased deposition of triglycerides (TGs) in nonadi-
ose tissue, such as the heart, liver, pancreas, and skeletal
uscle (1–4). There are indications from animal experi-
ents and human observations that the increase in myocar-
ial TG content is associated with altered myocardial
unction. In animal experiments, increased myocardial TG
ontent is associated with impaired myocardial function
5,6) via complex routes involving fatty acid (FA) deriva-
ives, such as FA acyl-coenzyme A and diacylglycerol (7–9).
n humans, myocardial TG content can be measured non-
rom the Departments of *Endocrinology and Metabolism, †Radiology, and ‡Gen-
ral Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
rs. Hammer and Snel contributed equally to this work.n
Manuscript received February 6, 2008; revised manuscript received April 4, 2008,
ccepted April 16, 2008.nvasively in vivo by proton magnetic resonance spectros-
opy (1HMRS) (10–14). These studies have documented
hat increased myocardial TG stores in obese subjects are
ccompanied by increased left ventricular (LV) mass (13)
nd changes in LV diastolic function (2).
See page 1013
In healthy subjects, myocardial TG stores are not fixed,
ut vary depending on nutritional conditions. For in-
tance, short-term caloric restriction dose-dependently
ncreases myocardial TG content (15), whereas a single
igh-fat meal does not affect myocardial TG stores (12).
ecently, we reported that the increase in myocardial TG
ontent induced by short-term caloric restriction is asso-
iated with impaired diastolic function in healthy
ormal-weight subjects (15,16). Caloric restriction is an
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September 16, 2008:1006–12 Myocardial Triglyceride Content in T2DMmportant lifestyle factor in the treatment of obese
atients with T2DM. However, the effects of caloric
estriction on myocardial TG content have not been
tudied in these patients.
Therefore, the primary goal of the present study was to
valuate the effects of prolonged caloric restriction in obese
atients with T2DM on myocardial TG content and LV
yocardial function in relation to metabolic regulation. In
ddition, T2DM is associated with ectopic deposition of
G in the liver (17,18). To assess the tissue-specific effects
f caloric restriction, we also assessed liver TG content in
hese obese T2DM patients.
ethods
atients. We studied 12 obese (body mass index [BMI],
ean  SEM: 35.6  1.2 kg/m2) T2DM patients (7 men,
women). The mean duration of T2DM was 9.6  1.4
ears. The patients’ age was 48.3  2.8 years. Patients were
ecruited from the outpatient clinic. All subjects used insulin
reatment (mean dosage 93  21 U/day) with or without
oncomitant use of oral blood glucose-lowering agents.
xclusion criteria were smoking; an abnormal stress elec-
rocardiogram (ECG); the use of other medication known
o influence lipolysis and/or glucose metabolism; and renal,
epatic, or other endocrine disease. Furthermore, subjects
ere excluded if the remaining insulin secretory capacity
as insufficient, defined by fasting C-peptide levels 0.8
g/l and/or2-fold increase after glucagon stimulation (1.0
g intravenously). This criterion was included because we
ocumented in a previous study that preservation of the
apacity of beta cells to secrete insulin predicts a favorable
etabolic response to a very-low-calorie diet (VLCD) in
bese T2DM patients (19,20). Body weight was stable for at
east 3 months, and subjects were instructed not to change
ifestyle habits (eating, drinking, and exercise) from screen-
ng until the start of the study. The protocol was approved
y the institutional ethical committee, and all subjects
rovided written informed consent before participation.
tudy design. The study consisted of 2 study occasions
eparated by a 16-week intervention period, during which
he subjects used a VLCD to induce substantial weight loss.
he VLCD consisted of 3 sachets of Modifast per day (450
cal/day, Nutrition & Santé, Antwerp, Belgium), providing
bout 50 g protein, 50 to 60 g carbohydrates, and 6 g lipids
aily. Three weeks before start of the intervention period, all
ral blood glucose–lowering drugs were discontinued and
he insulin therapy was intensified. Baseline magnetic res-
nance (MR) measurements were obtained in the post-
randial state (4 h after the last meal) within 1 week before
he start of the VLCD. Baseline blood samples were
btained after an overnight fast. At the start of the VLCD
nd during the whole intervention period, all glucose-
owering medication, including insulin, was discontinued.
ix of the 12 subjects followed an exercise program in
ddition to the VLCD, but were not different with respect po outcome parameters. After 16
eeks, MR measurements (4 h
fter the last meal) were re-
eated. Blood samples were
aken after an overnight fast.
HMRS of the heart and the
iver. All measurements were
erformed on a 1.5-T Gyroscan
CS-NT MR imaging scanner
Philips Medical Systems, Best,
he Netherlands) in the supine
osition. For 1HMRS measure-
ents, a body coil for radiofre-
uency transmission and a sur-
ace coil (diameter of 17 cm) for
ignal receiving were used. A
oint-resolved spatially localized
pectroscopic pulse sequence was
sed to acquire single-voxel (8 ml) spectra. For the heart,
he voxel was placed in the myocardial septum on
-chamber and short-axis images at end systole, avoiding
ontamination with epicardial fat. Data acquisition was
ouble-triggered using ECG triggering and navigator ech-
es to minimize breathing artifacts (14). For the liver, voxel
ites were matched at the study occasions (by using the 12th
horacic vertebra as an anatomical landmark), carefully
voiding blood vessels and bile ducts. Water-suppressed
pectra with 128 averages were collected to detect lipid
ignals from the heart, and suppressed spectra with 64
verages were acquired from the liver. Spectral parameters
ncluded: repetition time of at least 3,000 ms, echo time 26
s, and 1,024 data points over 1,000-kHz spectral width.
urthermore, unsuppressed spectra with 4 averages were
cquired in the same voxel, using the same parameters
xcept for a repetition time of 10 s. Spectra were analyzed in
he time domain, using the advanced MR algorithm in the
ava-based MR user interface software (jMRUI version 2.2,
. van den Boogaart, Katholieke Universiteit Leuven,
euven, Belgium) (21), as described earlier (14). Peak
stimates of lipid resonances of myocardial and hepatic TGs
t 1.3 and 0.9 ppm were summed and calculated as a
ercentage of the unsuppressed water signal (%TGs, TGs/
ater  100) and used in further analysis.
V function. Imaging was performed at 1.5 T in a single
ession together with spectroscopy measurements, using a body
oil for radiofrequency transmission and a 5-element synergy
oil for signal receiving. The heart was imaged in the short-axis
rientation using an ECG-triggered, sensitivity-encoding bal-
nced steady-state free procession sequence to assess systolic
unction. Imaging parameters were: field-of-view  400 
20 mm, matrix size  256  256, slice thickness  10 mm,
lice gap 0 mm, flip angle 35°, echo time 1.67 ms, and
epetition time  3.34 ms. Temporal resolution was 25 to 39
s (depending on the heart rate). End-diastolic and -systolic
mages were identified on all slices, and dedicated post-
Abbreviations
and Acronyms
1HMRS  proton magnetic
resonance spectroscopy
BMI  body mass index
ECG  electrocardiogram
FA  fatty acid
LV  left ventricular
MR  magnetic resonance
NEFA  nonesterified fatty
acids
T2DM  type 2 diabetes
mellitus
TG  triglyceride
VLCD  very-low-calorie
dietrocessing software (MASS, V2007-EXP, Leiden University
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Myocardial Triglyceride Content in T2DM September 16, 2008:1006–12edical Center, Medis, Leiden, the Netherlands) was used to
uantify LV ejection fraction, LV mass, cardiac output, stroke
olume, and end-diastolic and -systolic volume as described
reviously (22). Furthermore, we calculated cardiac index, LV
ass index, stroke volume index, end-diastolic index, and
nd-systolic index by dividing the parameter by body surface
rea. To asses LV diastolic function, an ECG-gated gradient-
cho sequence with velocity encoding was performed to mea-
ure blood flow across the mitral valve (23). Imaging parame-
ers were: echo time  5 ms, repetition time  14 ms,
ip-angle  20°, slice thickness  8 mm, field of view  350
m, matrix size 256 256, velocity encoding 100 cm/s,
nd scan percentage  80%. Flow velocities in early diastole
E) and at atrial contraction (A) were measured and their peak
ow ratio was calculated (E/A ratio) using the FLOW ana-
ytical software package (V2006-EXP, Leiden University
edical Center, Medis). Furthermore, the downslope of the
arly filling phase (E deceleration) and an estimation of LV
lling pressures (E/Ea) (24) were calculated. During MR
maging, blood pressure and heart rate were measured with an
utomatic device (Dinamap DPC100X, Freiburg, Germany).
ssays. Plasma glucose, total cholesterol, and TG concen-
rations were measured on a fully automated P800 analyzer
Roche, Almere, the Netherlands). Insulin was measured on
n Immulite 2500 random access analyzer with a chemolu-
inescence immunoassay (DPC, Los Angeles, California).
oefficients of variation were2% for glucose and5% for
nsulin. Plasma levels of nonesterified fatty acids (NEFA)
ere measured using a commercial kit (NEFA-C, Wako
hemicals, Neuss, Germany). The hemoglobin A1c levels
ere measured with an HPLC system (Variant, Biomed,
ercules, California). Leptin and adiponectin were mea-
ured with a radioimmunoassay from Linco Research (St.
harles, Missouri), with coefficients of variation ranging
rom 3.0% to 5.1% for leptin and 7% to 9% for adiponectin,
nd a sensitivity of 0.5 g/l. The high-sensitivity C-reactive
rotein enzyme-linked immunosorbent assay came from
SL (Webster, Texas). The sensitivity was 0.03 mg/l, and
A B
Figure 1 Fat Stores and Body Mass Index
Example of a transverse slice at the level of the 5th lumbar vertebrae showing vis
restriction in the same patient (A and B). Body mass index (BMI) is decreased afthe coefficient of variation was between 3% and 6%.
t
ttatistical analysis. All statistical analyses were per-
ormed with SPSS version 14.0 (SPSS Inc., Chicago,
llinois). Statistical comparisons between baseline mea-
urements and measurements after prolonged caloric
estriction were made by paired t test. Data are shown as
ean  SEM. A value of p  0.05 was considered to
eflect significant differences.
esults
etabolic parameters. Caloric restriction reduced BMI
rom 35.6 1.2 kg/m2 at baseline to 27.5 1.3 kg/m2 after
he intervention period (p  0.001) (Fig. 1). Metabolic
arameters before and after prolonged caloric restriction are
hown in Table 1 and Figure 2. After 16 weeks of VLCD,
lycemic control was significantly improved; fasting plasma
lucose levels decreased from 11.4  0.6 mmol/l at baseline
despite glucose lowering therapy by high-dose insulin) to
.7 0.6 mmol/l after prolonged caloric restriction (only on
VLCD without any glucose-lowering therapy for 16
∗
Baseline
BM
I (k
g/m
2 )
16 weeks VLCD
0
10
20
30
40C
nd subcutaneous fat depots, illustrating the effects of 16 weeks of caloric
longed caloric restriction (C). *p  0.001. VLCD  very-low-calorie diet.
etabolic Response to 16 Weeks ofaloric Restriction in Obese Patients With T2DM
Table 1 Metabolic Response to 16 Weeks ofCaloric Restriction in Obese Patients With T2DM
Fasting Plasma Concentrations Baseline
After 16 Weeks of
Caloric Restriction
Glucose (mmol/l) 11.4 0.6 6.7 0.6*
Hemoglobin A1c (%) 7.9 0.4 6.7 0.6†
Insulin (mU/l) 39 9‡ 10 3†
AST (mmol/l) 44 5 27 3†
ALT (mmol/l) 52 12 23 3§
GT (mmol/l) 38 5 18 2†
Total cholesterol (mmol/l) 5.7 0.5 4.8 0.2§
Nonesterified fatty acids (mmol/l) 0.92 0.07 0.67 0.05*
TG (mmol/l) 2.1 0.3 1.1 0.1*
Leptin (g/l) 21.5 4.3 7.6 3.4*
Adiponectin (g/l) 5.2 0.7 7.8 1.1†
hs-CRP (mg/l) 18.5 4.2 7.5 2.0†
ata are mean SEM.*p 0.001; †p 0.01 versus baseline; ‡insulin (short acting) was stopped
12 h; §p  0.05 versus baseline.
GT  gamma-glutamyl transferase; ALT  alanine aminotransferase; AST  aspartate amino-ceral a
er proransferase; hs-CRP  high-sensitive C-reactive protein; T2DM  type 2 diabetes mellitus; TG 
riglyceride.
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September 16, 2008:1006–12 Myocardial Triglyceride Content in T2DMeeks, p  0.001). Furthermore, hemoglobin A1c levels
ecreased from 7.9  0.4% to 6.3  0.3% at baseline and
fter prolonged caloric restriction, respectively, p  0.006).
lasma NEFA levels were 0.92  0.07 mmol/l at baseline
nd decreased to 0.67 0.05 mmol/l after prolonged caloric
estriction (p  0.001) (Fig. 2A). Furthermore, plasma
evels of liver enzymes, total cholesterol, TGs, leptin, and
-reactive protein were significantly decreased after the
LCD compared with baseline, whereas plasma adiponec-
in levels were increased (Table 1, Fig. 2).
yocardial and hepatic TG content. Typical myocardial
roton spectra of a patient at baseline and after caloric
estriction are shown in Figure 3. Myocardial TG content
ecreased from 0.88  0.12% (baseline) to 0.64  0.14%
after the VLCD, p  0.019, based on n  11 successful
yocardial spectral measurements) (Fig. 2C). Concomi-
antly, hepatic TG content decreased from 21.2  4.2% to
.0  0.9%, respectively (p  0.001) (Fig. 2D).
yocardial systolic and diastolic function. Systolic blood
ressure decreased from 144  8 mm Hg to 118  6 mm
g at baseline and after substantial weight loss, respectively
p  0.001). Diastolic blood pressure decreased from 81 
mm Hg at baseline to 71  2 mm Hg after weight loss
p  0.001). Heart rate was significantly decreased after
ubstantial weight loss (Table 2).
During caloric restriction, myocardial function improved.
ardiac output decreased significantly from 7,971  601
l/min at baseline to 6,508  401 ml/min after prolonged
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m
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Figure 2 Metabolic Changes at Baseline and After 16 Weeks o
Changes in plasma NEFA (A), plasma TG levels (B), and myocardial (C), and hepa
mean  SEM. NEFA  nonesterified fatty acids; TG  triglyceride; VLCD  very-loaloric restriction (p  0.001). Furthermore, LV mass was pignificantly decreased as well (from 118  7 g to 99  6 g,
espectively, p  0.001) (Fig. 4A). The E/A ratio increased
rom 1.02  0.08 at baseline to 1.18  0.06 after the
LCD (p  0.019), reflecting improved diastolic function
Fig. 4B).
iscussion
his study shows that prolonged caloric restriction de-
reases BMI and considerably improves glucoregulation,
ssociated with decreased myocardial TG content and
eneficial effects on blood pressure and myocardial function
n insulin-treated obese patients with T2DM. The data
rove that myocardial TG stores in obese patients with
2DM are flexible and amendable to therapeutic interven-
ion by caloric restriction.
yocardial TG content. Myocardial TG accumulation is
he net result of excessive FA uptake in relation to oxidative FA
equirements. In animal experiments, this increased myocardial
G pool is associated with impaired myocardial function (5,6).
n human studies, myocardial TG accumulation is also asso-
iated with impaired myocardial function. For instance, a
ost-mortem study in obese patients with severe metabolic
ysregulation and heart failure documented myocardial lipid
ccumulation that was higher in subjects suffering from obesity
nd T2DM (25). Recently, McGavock et al. (2) documented
hat in patients with T2DM myocardial TG content is
ncreased, and suggested that myocardial TG accumulation
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Myocardial Triglyceride Content in T2DM September 16, 2008:1006–12ardial TG content may be an interesting marker for the risk of
onischemic heart disease, and a potential surrogate marker for
ssessing the effects of metabolic interventions on the heart. In
odents, the restoration of myocardial TG metabolism is
ssociated with improvements in cardiac function (6,26), in
ccordance with our findings. Nonetheless, the improvement
n myocardial function on caloric restriction in the present
tudy cannot merely be ascribed to the decreased myocardial
Figure 3 Myocardial Proton Spectra
Typical unsuppressed proton spectra of the same patient at baseline and after
16 weeks of caloric restriction (A). The starred boxes indicate the part of
spectrum where the myocardial lipids resonate, of which the suppressed spec-
tra are shown in (B). ppm parts per million; other abbreviations as in Figure 2.G stores, because there were also major alterations in other
E
Tactors that affect cardiac mass and function, such as BMI and
lood pressure.
yocardial function. Others reported beneficial effects
f weight loss on cardiac function after bariatric surgery
27) or VLCD (28). Moreover, we found a decrease in
eart rate, which is beneficial because heart rate is
ndependently associated with increased mortality (29).
n addition to this decreased heart rate, we observed a
ecrease in cardiac output and LV mass, in line with
reviously reported data (30). The LV ejection fraction
as normal and did not change after the intervention
eriod, in accordance with previous data showing that
ormal LV ejection fraction was unchanged 3 months
fter weight loss in obese subjects (31). The LV mass is
redictive of cardiovascular morbidity and mortality and
an be decreased by improvements in blood pressure (32).
n addition, the decrease we found in LV mass is
nfluenced by the substantial weight loss (33) and possi-
ly by the improvements in insulin sensitivity (34).
ecause of the dramatic changes in body size, some of the
ndexed values for LV dimensions were changed after the
ntervention period. The LV mass index decreased,
hereas the end-diastolic index was increased.
The decrease in LV mass can directly influence LV filling
ressures, and consequently, parameters of LV diastolic func-
ion (35). However, the presently used estimation of LV filling
ressures (E/Ea) showed no changes after prolonged caloric
estriction. Therefore, an alternative explanation for the in-
rease in the E/A ratio may be improved elastic properties of
he LV, in line with results from animal models, documenting
he relationship between myocardial TG accumulation and
ntraindividual Effects of 16 Weeks of Caloricestriction on Systolic and Diastolic Function inbese Patients Wi h T2DM
Table 2
Intraindividual Effects of 16 Weeks of Caloric
Restriction on Systolic and Diastolic Function in
Obese Patients With T2DM
Baseline
After 16 Weeks of
Caloric Restriction
Systolic blood pressure (mm Hg) 144 8 118 6*
Diastolic blood pressure (mm Hg) 81 2 71 2*
Heart rate (beats/min) 78 3 61 2*
LVEF (%) 57 2 58 2
Stroke volume (ml) 102 6 103 8
Stroke volume index (ml/m2) 45 2 51 3†
Cardiac output (ml/min) 7,971 601 6,508 401‡
Cardiac index (l/min/m2) 3.5 0.2 3.2 0.2
LV mass (g) 118 7 99 6*
LV mass index (g/m2) 53 3 49 3†
ED volume (ml) 177 8 177 11
ED index (ml/m2) 79 3 88 4†
ES volume (ml) 76 4 74 5
ES index (ml/m2) 34 2 37 2
E deceleration (ml/s2  103) 4.04 0.50 4.30 0.42
E/A peak ratio 1.02 0.08 1.18 0.06†
E/Ea 11.9 1.2 11.4 1.5
ata are mean  SEM. *p  0.001; †p  0.05 versus baseline; ‡p  0.01 versus baseline.
A atrial filling phase; E early filling phase; E/Ea estimated left ventricular filling pressure;
D end-diastolic; ES end-systolic; LV left ventricular; LVEF left ventricular ejection fraction;
2DM  type 2 diabetes mellitus.
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September 16, 2008:1006–12 Myocardial Triglyceride Content in T2DMyocardial function (5,6). One of the alternative mechanisms
ay be that changes in plasma FAs change the calcium
omeostasis in the myocardium (36), which influences LV
iastolic function (37). Furthermore, the present improve-
ents in the inflammatory parameter C-reactive protein may
nfluence myocardial function as well (38).
etabolic improvements. In addition to the decrease in
yocardial TG content, the VLCD dramatically decreased
epatic TG content, associated with improvements in
lasma lipid profile and liver enzymes. Moreover, insulin
ensitivity was markedly increased after substantial weight
oss, in accordance with previous studies (19,20,39,40). The
mprovement in hepatic TG content indicates that there is
 general reduction in ectopic deposition of TGs in nona-
ipose tissues, including the liver and heart.
tudy limitations. First, the study is descriptive and does
Baseline 16 weeks VLCD
50
75
100
125
150
175
LV
 M
as
s 
(g)
*
Baseline 16 weeks VLCD
0.00
0.25
0.50
0.75
1.00
1.25
1.50
E/
A 
Ra
tio
†
†
A
B
Figure 4 Changes in Myocardial Function
Intraindividual changes in left ventricular (LV) mass (A) and the ratio between
the early filling phase and the atrial filling phase (E/A ratio) on progressive
caloric restriction (B). *p  0.001; ‡p  0.05. VLCD  very-low-calorie diet.ot establish a causal relationship between myocardial TG
1ccumulation and myocardial function, although the results
re in accordance with data obtained in different animal
odels of obesity and, additionally, show the metabolic
exibility of the diabetic heart. Second, the sample size is
elatively small. However, the patients are their own con-
rols, and the magnitude of the metabolic and functional
hanges is illustrative because it indicates dynamic features
f myocardial TGs and diastolic function.
onclusions
rolonged caloric restriction in obese T2DM patients de-
reases BMI and improves glucoregulation associated with
ecreased myocardial TG content and improved diastolic
eart function. Therefore, myocardial TG stores in obese
atients with T2DM are flexible and amendable to thera-
eutic intervention by caloric restriction.
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